Doxanthrine
 | |
| Clinical data | |
|---|---|
| ATC code | none |
| Identifiers | |
| |
| PubChem (CID) | 15981509 |
| ChemSpider | 13112900 |
| Chemical and physical data | |
| Formula | C16H15NO3 |
| Molar mass | 269.295 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
Doxanthrine is a synthetic compound which is a potent and selective full agonist for the dopamine D1 receptor.[1][2] Doxanthrine has been shown to be orally active in producing contralateral rotation in the 6-hydroxy-dopamine rat model of Parkinson's disease.[3]
References
- ↑ Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE (November 2006). "trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist". Journal of Medicinal Chemistry. 49 (23): 6848–57. doi:10.1021/jm0604979. PMID 17154515.
- ↑ Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ (February 2009). "Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 19 (2): 138–46. doi:10.1016/j.euroneuro.2008.10.002. PMC 2636714
. PMID 19028082. - ↑ McCorvey JD, Watts VJ, Nichols DE (July 2012). "Comparison of the D1 dopamine full agonists,dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease". Psychopharmacology (Berl). 222 (1): 81–87. doi:10.1007/s00213-011-2625-5. PMID 22222862.
This article is issued from Wikipedia - version of the 11/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.